Table 1 Subject demographic and clinical characteristics
From: The economic burden of pulmonary arterial hypertension (PAH) in the US on payers and patients
Final PAH study sample (N = 504) | ||
|---|---|---|
Mean | SD | |
Age, years | 49.73 | 19.79 |
n | % | |
Male gender | 117 | 23.21 |
Geographic region | ||
Northeast | 45 | 9.15 |
Midwest | 148 | 30.08 |
South | 216 | 43.90 |
West | 83 | 16.87 |
Insurance | ||
Commercial | 439 | 87.10 |
Medicare | 65 | 12.90 |
Baseline comorbidities | ||
Diseases of the heart | 491 | 97.42 |
Lower respiratory disease | 433 | 85.91 |
Hypertension | 298 | 59.13 |
Diseases of arteries, arterioles, and capillaries | 267 | 52.98 |
Systemic lupus erythematosus and connective tissue disorders | 261 | 51.79 |
Respiratory infections | 188 | 37.30 |
Upper gastrointestinal disorders | 182 | 36.11 |
Non-traumatic joint disorders | 181 | 35.91 |
Connective tissue disease | 170 | 33.73 |
Injuries and conditions due to external causes | 163 | 32.34 |
Diseases of the urinary system | 162 | 32.14 |
Chronic obstructive pulmonary disease and bronchiectasis | 156 | 30.95 |
Disorders of lipid metabolism | 153 | 30.36 |
Gastrointestinal disorders | 141 | 27.98 |
Cardiac and circulatory congenital anomalies | 136 | 26.98 |
Anemia | 133 | 26.39 |